|By Marketwired .||
|June 10, 2014 05:26 PM EDT||
VANCOUVER, BC--(Marketwired - June 10, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB), (the "Company") is pleased to announce that all resolutions tabled at its Annual General and Special Meeting held on June 10, 2014, were passed. The resolutions included:
- Election of Geraldine Deliencourt-Godefroy, Christopher Hopton, Alex Marazzi, David Moore, Michael Rogers, Nigel Terrett and Howard Verrico as directors;
- Appointment of auditor and authorization of the directors to fix the auditor's remuneration;
- Adoption of a 2014 Stock Option Plan;
- Adoption of new Articles of the Company.
The new Articles will bring the Company up to date with current corporate practices, including incorporating advance notice provisions with respect to election of directors (the "Advance Notice Provisions"). The Advance Notice Provisions will ensure an orderly nomination process of directors, ensure that shareholders are well-informed about the identity, intentions and credentials of director nominees and ensure that shareholders vote in an informed manner after having been afforded reasonable time for appropriate deliberation.
The new Articles are available on SEDAR under the Company's profile and shareholders are encouraged to review the Articles in their entirety.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Email: [email protected]
Sep. 27, 2016 04:45 PM EDT Reads: 315
Sep. 27, 2016 04:00 PM EDT Reads: 2,627
Sep. 27, 2016 03:30 PM EDT Reads: 284
Sep. 27, 2016 03:15 PM EDT Reads: 2,852
Sep. 27, 2016 03:15 PM EDT Reads: 2,756
Sep. 27, 2016 03:15 PM EDT Reads: 1,357
Sep. 27, 2016 03:00 PM EDT Reads: 1,689
Sep. 27, 2016 02:45 PM EDT Reads: 1,252
Sep. 27, 2016 02:45 PM EDT Reads: 2,201
Sep. 27, 2016 02:45 PM EDT Reads: 4,634
Sep. 27, 2016 02:15 PM EDT Reads: 1,991
Sep. 27, 2016 02:00 PM EDT Reads: 1,443
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
Sep. 27, 2016 01:30 PM EDT Reads: 1,713
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. Big Data at Cloud Expo - to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is...
Sep. 27, 2016 01:00 PM EDT Reads: 2,661
IoT is fundamentally transforming the auto industry, turning the vehicle into a hub for connected services, including safety, infotainment and usage-based insurance. Auto manufacturers – and businesses across all verticals – have built an entire ecosystem around the Connected Car, creating new customer touch points and revenue streams. In his session at @ThingsExpo, Macario Namie, Head of IoT Strategy at Cisco Jasper, will share real-world examples of how IoT transforms the car from a static p...
Sep. 27, 2016 01:00 PM EDT Reads: 1,596